The aim was to examine anti-tumor necrosis factor α (anti-TNFα) therapy influence changes on Th17 and Th22 cells in patients with spondyloarthritis (SpA), and its correlation with changes in clinical and magnetic resonance imaging (MRI) activity and chronicity scores. The Th17 and Th22 cells were assessed at baseline, after 12 and 52 weeks of anti-TNFα therapy by flow cytometry (ClinicalTrials.gov NCT4682724). The percentages of both Th17 and Th22 cells were increased by 70% at baseline compared with healthy controls (both p < 0.01). During treatment, these two subsets increased further to be 170% (Th17) and 123% (Th22) above levels in healthy controls (both p < 0.01). The same subsets decrease their expression of IL-23R significantly during the observation period (p < 0.05). High levels of Th17 and Th22 cells at baseline were associated with the degree of chronic changes in the sacroiliac joints on MRI and a good clinical response to anti-TNFα treatment after one year. Plasma levels were not associated with clinical changes. Th17 cells, and Th22 subsets, increased during one year of anti-TNF-α therapy in SpA, regardless of their clinical improvement. This supports that both the Th17 and Th22 subsets could be involved in the progression in SpA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apm.12994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inborn errors of immunity reveal molecular requirements for generation and maintenance of human CD4 IL-9-expressing cells.
J Allergy Clin Immunol
November 2024
Garvan Institute of Medical Research, Darlinghurst, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Sydney, Australia. Electronic address:
Background: CD4 T cells play essential roles in adaptive immunity. Distinct CD4 T-cell subsets-T1, T2, T17, T22, T follicular helper, and regulatory T cells-have been identified, and their contributions to host defense and immune regulation are increasingly well defined. IL-9-producing T9 cells were first described in 2008 and appear to play both protective and pathogenic roles in human immunity.
View Article and Find Full Text PDFAutoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP).
Autoimmun Rev
December 2024
Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden; Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne, Lund, Sweden; Departments of Pharmacology, Medicine and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. Electronic address:
Article Synopsis
- Immune thrombocytopenia (ITP) is an autoimmune disorder marked by low platelet counts, with varying symptoms ranging from no bleeding to severe, potentially fatal bleeding.
- The disease involves a malfunction in the immune system, particularly a hyperactive response from certain immune cells that destroy platelets and their precursors.
- Key factors in this condition include a breakdown of immune regulation, characterized by defects in certain immunosuppressive cells, leading to an uncontrolled immune response that attacks platelets and disrupts their production.
Age-specific dynamics of neutralizing antibodies, cytokines, and chemokines in response to La Crosse virus infection in mice.
J Virol
December 2024
Rutgers Global Health Institute, Rutgers University, New Brunswick, New Jersey, USA.
La Crosse virus (LACV) is a primary cause of pediatric arboviral encephalitis in the United States, particularly affecting children aged 16 years or younger. This age-related susceptibility extends to murine models, where weanling mice (3 weeks old) succumb to LACV infection, while adults (≥6 weeks old) demonstrate resistance. Despite its clinical relevance, the host immune response to LACV is not fully understood.
View Article and Find Full Text PDFSystematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.
Front Immunol
November 2024
Eli Lilly and Company, Indianapolis, IN, United States.
Article Synopsis
- - Current treatments for autoimmune diseases often fail to achieve long-term remission, prompting interest in therapies that restore balance in the immune system, known as immune resolution; however, there's no clear consensus on how to evaluate these therapies in clinical trials.
- - A systematic literature review (SLR) was conducted using established guidelines to explore expert opinions and previous studies on immune resolution in five autoimmune diseases: asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis; this involved searching databases and conference proceedings from 2013 to 2023.
- - The SLR included 26 publications and found that expert opinions tended to lack specific measures for assessing immune resolution but suggested potential targets and biomarkers for future therapy
Profile of immune response during nasal challenge with dermatophagoides pteronyssinus in subjects with allergic airway diseases.
J Inflamm (Lond)
October 2024
Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Background: T lymphocyte helper (Th) 2 plays the main role in pathogenesis of allergic airway diseases (AAD). Recent studies showed that interleukin (IL) 33, Th17 and Th22 also may be involved in allergic inflammation. The aim is to evaluate cytokine level before and after nasal challenge with Dermatophagoides pteronyssinus in patients with AAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!